These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 25546779)

  • 1. Will sialylation change intravenous immunoglobulin therapy in the future?
    Käsermann F; Campbell IK
    Clin Exp Immunol; 2014 Dec; 178 Suppl 1(Suppl 1):100-2. PubMed ID: 25546779
    [No Abstract]   [Full Text] [Related]  

  • 2. Role of sialylation in the anti-inflammatory activity of intravenous immunoglobulin - F(ab')₂ versus Fc sialylation.
    Schwab I; Nimmerjahn F
    Clin Exp Immunol; 2014 Dec; 178 Suppl 1(Suppl 1):97-9. PubMed ID: 25546778
    [No Abstract]   [Full Text] [Related]  

  • 3. 7th International Immunoglobulin Conference: Mechanisms of action.
    Basta M; Branch DR
    Clin Exp Immunol; 2014 Dec; 178 Suppl 1(Suppl 1):111. PubMed ID: 25546783
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 7th International Immunoglobulin Conference: Mechanisms of action.
    Basta M; Branch DR
    Clin Exp Immunol; 2014 Dec; 178 Suppl 1(Suppl 1):87-8. PubMed ID: 25546774
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anti-inflammatory activity of immunoglobulin G resulting from Fc sialylation.
    Kaneko Y; Nimmerjahn F; Ravetch JV
    Science; 2006 Aug; 313(5787):670-3. PubMed ID: 16888140
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intravenous immunoglobulins neutralize blocking antibodies in Guillain-Barré syndrome.
    Buchwald B; Ahangari R; Weishaupt A; Toyka KV
    Ann Neurol; 2002 Jun; 51(6):673-80. PubMed ID: 12112071
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunoglobulin G Fc N-glycosylation in Guillain-Barré syndrome treated with intravenous immunoglobulin.
    Fokkink WJ; Selman MH; Wuhrer M; Jacobs BC
    Clin Exp Immunol; 2014 Dec; 178 Suppl 1(Suppl 1):105-7. PubMed ID: 25546781
    [No Abstract]   [Full Text] [Related]  

  • 8. Intravenous immunoglobulin and immune response.
    Kaveri SV; Lecerf M; Saha C; Kazatchkine MD; Lacroix-Desmazes S; Bayry J
    Clin Exp Immunol; 2014 Dec; 178 Suppl 1(Suppl 1):94-6. PubMed ID: 25546777
    [No Abstract]   [Full Text] [Related]  

  • 9. Immunology. Sugar determines antibody activity.
    Burton DR; Dwek RA
    Science; 2006 Aug; 313(5787):627-8. PubMed ID: 16888131
    [No Abstract]   [Full Text] [Related]  

  • 10. Optimizing immunoglobulin G therapy in chronic autoimmune neuropathies.
    Berger M
    Clin Exp Immunol; 2014 Dec; 178 Suppl 1(Suppl 1):144-5. PubMed ID: 25546798
    [No Abstract]   [Full Text] [Related]  

  • 11. Dose and outcomes in primary immunodeficiency disorders.
    Bonagura VR
    Clin Exp Immunol; 2014 Dec; 178 Suppl 1(Suppl 1):7-9. PubMed ID: 25546743
    [No Abstract]   [Full Text] [Related]  

  • 12. Intravenous immunoglobulin in autoimmune and inflammatory diseases: more than mere transfer of antibodies.
    Sibéril S; Elluru S; Negi VS; Ephrem A; Misra N; Delignat S; Bayary J; Lacroix-Desmazes S; Kazatchkine MD; Kaveri SV
    Transfus Apher Sci; 2007 Aug; 37(1):103-7. PubMed ID: 17765663
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Normal human polyclonal immunoglobulins delay xenograft rejection through distinct F(ab')2 and Fc mediated mechanisms.
    Genevaz D; Latremouille C; Goussev N; Carpentier A; Glotz D
    Transplant Proc; 1996 Apr; 28(2):853-4. PubMed ID: 8623433
    [No Abstract]   [Full Text] [Related]  

  • 14. Controlled tetra-Fc sialylation of IVIg results in a drug candidate with consistent enhanced anti-inflammatory activity.
    Washburn N; Schwab I; Ortiz D; Bhatnagar N; Lansing JC; Medeiros A; Tyler S; Mekala D; Cochran E; Sarvaiya H; Garofalo K; Meccariello R; Meador JW; Rutitzky L; Schultes BC; Ling L; Avery W; Nimmerjahn F; Manning AM; Kaundinya GV; Bosques CJ
    Proc Natl Acad Sci U S A; 2015 Mar; 112(11):E1297-306. PubMed ID: 25733881
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Protein-glycan interactions as targets of intravenous/subcutaneous immunoglobulin (IVIg/SCIg) preparations.
    von Gunten S
    Clin Exp Immunol; 2014 Dec; 178 Suppl 1(Suppl 1):151-2. PubMed ID: 25546801
    [No Abstract]   [Full Text] [Related]  

  • 16. Sialylation-independent mechanism involved in the amelioration of murine immune thrombocytopenia using intravenous gammaglobulin.
    Leontyev D; Katsman Y; Ma XZ; Miescher S; Käsermann F; Branch DR
    Transfusion; 2012 Aug; 52(8):1799-805. PubMed ID: 22257295
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anti-inflammatory actions of intravenous immunoglobulin.
    Nimmerjahn F; Ravetch JV
    Annu Rev Immunol; 2008; 26():513-33. PubMed ID: 18370923
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anti-coagulation effect of Fc fragment against anti-β2-GP1 antibodies in mouse models with APS.
    Xie W; Zhang Y; Bu C; Sun S; Hu S; Cai G
    Int Immunopharmacol; 2011 Jan; 11(1):136-40. PubMed ID: 21078423
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The pro and anti-inflammatory activities of immunoglobulin G.
    Lux A; Aschermann S; Biburger M; Nimmerjahn F
    Ann Rheum Dis; 2010 Jan; 69 Suppl 1():i92-96. PubMed ID: 19995755
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Quantitative glycan profiling of normal human plasma derived immunoglobulin and its fragments Fab and Fc.
    Anumula KR
    J Immunol Methods; 2012 Aug; 382(1-2):167-76. PubMed ID: 22683540
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.